OPKO Health, Inc. is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.
OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions. Its products include Rayaldee, an extended-release formulation of calcifediol used to treat secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency. The company has also been involved in the development and commercialization of growth hormone therapies, including somatrogon, which is marketed in certain regions through a collaboration with Pfizer.
Headquartered in Miami, Florida, OPKO serves customers and patients in the United States and internationally through its laboratory, diagnostic and pharmaceutical activities. The company expanded its laboratory presence through the acquisition of Bio-Reference Laboratories in 2015. OPKO is led by Phillip Frost, who serves as executive chairman and chief executive officer.
AI Generated. May Contain Errors.
Free OPK Stock Alerts